

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/432,881	11/02/1999	MICHELINE MARKEY	15662-000900	1727
20350 7.	590 , 03/17/2003	•		
TOWNSEND AND TOWNSEND AND CREW, LLP TWO EMBARCADERO CENTER EIGHTH FLOOR SAN FRANCISCO, CA 94111-3834			EXAMINER	
			WEBMAN, E	DWARD J
			ART UNIT	PAPER NUMBER
			1617	92
			DATE MAILED: 03/17/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No. 69/43288/ Applicant(s) MARKEY
Office Action Summary	Examiner Group Art Unit 1617
-The MAILING DATE of this communication appear	s on the cover sheet beneath the correspondence address-
P ri d for Reply	_
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO OF THIS COMMUNICATION.	EXPIRE MONTH(S) FROM THE MAILING DATE
from the mailing date of this communication.	· · · · · · · · · · · · · · · · · · ·
Status	
Responsive to communication(s) filed on/	2/12/02
☐ This action is FINAL.	,
 Since this application is in condition for allowance except the accordance with the practice under Ex parte Quayle, 1935 	or formal matters, prosecution as to the merits is closed in C.D. 1 1; 453 O.G. 213.
Disposition of Claims	
Claim(s) 1 - 9 9	is/are pending in the application.
Of the above claim(s) $3-5$, $7-13$, 19	is/are pending in the application. -47, 52-99 is/are withdrawn from consideration. is/are allowed. is/are rejected.
□ Claim(s)	is/are allowed.
(Claim(s) 1, 2, 6, 14-18, 47	is/are rejected.
☐ Claim(s)	is/are objected to.
	are subject to restriction or election requirement.
Application Papers	roquionia.
$\ \square$ See the attached Notice of Draftsperson's Patent Drawing	Review, PTO-948.
☐ The proposed drawing correction, filed on	
☐ The drawing(s) filed on is/are objects	ed to by the Examiner.
 □ The specification is objected to by the Examiner. □ The oath or declaration is objected to by the Examiner. 	
Priority under 35 U.S.C. § 119 (a)-(d)	
☐ Acknowledgment is made of a claim for foreign priority und	dor 25 U.S.C. & 44 O(a) (d)
 □ All □ Some* □ None of the CERTIFIED copies of the received. 	• • • • • • • • • • • • • • • • • • • •
 □ received in Application No. (Series Code/Serial Number □ received in this national stage application from the Inter 	·
*Certified copies not received:	•
Attachment(s)	
☐ Information Disclosure Statement(s), PTO-1449, Paper No	(s) □ Interview Summary, PTO-413
Notice of Reference(s) Cited, PTO-892	☐ Notice of Informal Pat nt Application, PTO-152
☐ Notice of Draftsperson's Patent Drawing Review, PTO-948	☐ Other
Office	Acti n Summary

Application/Control Number: 09/432,881

Art Unit: 1617

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1, 2, 6, 14-18, 48-51 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shell (WO 97/47285, see IDS paper no. 8 filed on July 2, 2001) in view of Acharya (US Patent No. 5,686,094) Sewester et al. (Facts and Comparisons) and Hsiao.

Shell (WO 97/47285) teaches a controlled release composition comprising an active drug and a solid matrix which swells or expands upon contact with gastric fluid in the fed mode (see page 4, line 32).

Shell does not teach an active drug docusate.

Acharya teaches docusate as a laxative (see column 7, lines 39, 57-58 and column 8, line 6). Controlled release is disclosed (see column 5, line 44). Hydroxypropyl cellulose is specified (see column 5, lines 53-54).

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to add docusate to the composition of Shell to achieve the beneficial effect of an additional laxative treatment in view of Acharya.

As to the claimed amount of docusate, it is well known in the art that the therapeutic range of docusate is within the claimed invention (see Facts and Comparisons, page 322a).

Page 3

Application/Control Number: 09/432,881

Art Unit: 1617

Applicants argue Docusate is a drug which should be released in the colon not the stomach. However, Hsiao teaches a device for release of drugs in the stomach, like Shell. (column 2 lines 48-52). Docusate is disclosed (column 7 lines 1-2). Clearly, then, delivery of the Acharya Docusate in the stomach-releasing vehicle of Shell as a Laxative would be recognized by one with ordinary skill as a workable combination in view of the Hsiao Disclosure.

No claims allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Edward Webman whose telephone number is (703) 308-4432. The examiner can normally be reached on Monday to Friday 9 Am 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, S. Padmanabhan can be reached on (703) 305-1877. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3592 for regular communications and (703) 305-3592 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Webman/LR February 25, 2003